
|Articles|May 15, 2017
- BioPharm International-05-15-2017
- Volume 2017 eBook
- Issue 1
Getting Biopharmaceutical Tech Transfer Right the First Time
Author(s)Agnes Shanley
Good project management, budgeting, planning, and clear documentation are the only ways to prevent overruns and project failure.
Advertisement
Biopharmaceutical experts Stephen Perry, CEO of Kymanox, James Blackwell, principal consultant with The Windshire Group, and consultant Mike Ultee, share best practices and musts to avoid in biopharmaceutical technology transfer. Some crucial takeaways? Share all data (especially data on failed runs in the past), and include clear instructions for sampling. In addition, aim for reproducibility.
Articles in this issue
over 9 years ago
Customer Relationship Management in Contract Manufacturingover 9 years ago
CMOs Tackle New Challengesover 9 years ago
Gearing Up for Biosimilarsover 9 years ago
Insourcing vs Outsourcing: Choosing the Right Strategyover 9 years ago
Operations and Quality Oversight of CMOsover 9 years ago
Quality Metrics and CMO AgreementAdvertisement
Related to this article

Merck's Dr Dave Maraldo outlines 3 principles for placing manufacturing capacity and how end-to-end ADC supply chains could shift platform thinking.

Donidalorsen sustained a 95% reduction in hereditary angioedema attacks over 2 years, and patients switching from other prophylaxis saw a 71% drop.

A single 240 mg dose of WVE-007 cut visceral fat while preserving lean mass for 1 year, as Activin E fell by up to 88% across INLIGHT dose groups.

This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
Advertisement
Advertisement
Trending on BioPharm International
1
FDA Approves AstraZeneca's Gefurulimab (Klygefa) for Generalized MG
2
FDA Reportedly Pauses National Priority Voucher Pilot and Pauses CRL Publication
3
Ionis Reports 2-Year Donidalorsen (Dawnzera) Data in HAE Prophylaxis
4
Deals Roundup: J&J Buys Ollin, Lilly Adds Calytrix, and Novartis and Sanofi Strike Platform Pacts
5



